ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Consensus Rating of “Moderate Buy” from Analysts

ALX Oncology Holdings Inc. (NASDAQ:ALXO) has been assigned an average rating of “Moderate Buy” from the six research firms that are currently covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $12.50.

ALXO has been the subject of several research reports. UBS Group decreased their price objective on shares of ALX Oncology from $25.00 to $4.00 and set a “buy” rating for the company in a research note on Friday, August 16th. Cantor Fitzgerald reiterated an “overweight” rating on shares of ALX Oncology in a report on Tuesday, November 12th. HC Wainwright restated a “buy” rating and set a $25.00 price objective on shares of ALX Oncology in a research note on Tuesday, August 13th. Finally, Stifel Nicolaus reiterated a “hold” rating and issued a $3.00 target price (down previously from $5.00) on shares of ALX Oncology in a research note on Friday, August 9th.

Hedge Funds Weigh In On ALX Oncology

A number of institutional investors have recently added to or reduced their stakes in ALXO. CANADA LIFE ASSURANCE Co acquired a new stake in ALX Oncology during the 1st quarter valued at approximately $27,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of ALX Oncology by 394.8% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,517 shares of the company’s stock valued at $39,000 after buying an additional 5,200 shares during the last quarter. SG Americas Securities LLC grew its position in shares of ALX Oncology by 33.6% during the third quarter. SG Americas Securities LLC now owns 27,394 shares of the company’s stock worth $50,000 after buying an additional 6,888 shares in the last quarter. Hsbc Holdings PLC bought a new stake in shares of ALX Oncology in the second quarter worth $63,000. Finally, GSA Capital Partners LLP acquired a new stake in ALX Oncology in the third quarter valued at $88,000. Institutional investors and hedge funds own 97.97% of the company’s stock.

ALX Oncology Stock Up 12.2 %

Shares of NASDAQ:ALXO opened at $1.66 on Thursday. The stock has a 50-day simple moving average of $1.54 and a 200-day simple moving average of $4.37. The stock has a market capitalization of $87.55 million, a P/E ratio of -0.56 and a beta of 1.03. ALX Oncology has a 1 year low of $1.19 and a 1 year high of $17.83. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.82 and a current ratio of 4.82.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.